Systematic Review of Protease Inhibitor Monotherapy and the PROTEA Study Presented by Janssen at HIV Drug Therapy Glasgow Congress

*Darunavir shows potential for the basis of a maintenance monotherapy in HIV for subset of patients with CD4 nadir of at least 200 cells/µL*

**Glasgow, Scotland, Thursday 6 November 2014** - Janssen R&D Ireland (Janssen) today announced data from the primary endpoint of the PROTEase Inhibitor (DRV/rtv) in mono- or triple therapy in suppressed human immunodeficiency virus (HIV)-1 infected subjects (PROTEA) study, and a systematic review of 12 clinical trials. Both the study and the review examined the boosted protease inhibitor darunavir as a possible basis for future maintenance monotherapy treatment for people living with HIV. The data were presented at the HIV Drug Therapy Glasgow 2014 Congress in Scotland.

The systematic review was based on 12 randomised trials (four studies evaluated darunavir/ritonavir [DRV/rtv] monotherapy, seven studies evaluated lopinavir/ritonavir [LPV/rtv] monotherapy and one study evaluated both DRV/rtv and LPV/rtv as monotherapies) of 2,202 patients with established HIV-1 RNA suppression comparing Protease Inhibitor (PI) monotherapy to triple therapy. Results from the systematic review showed that PI monotherapy compared to triple therapy showed lower HIV suppression rates (76% versus 82%); however, after treatment re-intensification with Nucleotide Reverse Transcriptase Inhibitors (NRTIs), the suppression rates were similar between the PI monotherapy and triple therapy arms (87% versus 85%). PIs are currently not licensed to be used in HIV maintenance monotherapy.

The findings from the systematic review were consistent with data from the 48-week analysis of the primary endpoint of the PROTEA study (designed to run for 96-weeks in total), which included 273 patients with established HIV-1 RNA suppression. The PROTEA study compared boosted darunavir monotherapy to triple therapy, with similarly lower HIV suppression rates (86% versus 95%). However, among the subset of patients with a CD4 nadir of at least 200 cells/µL, the PROTEA study showed very high HIV suppression rates of both the PI monotherapy and the triple therapy arm (95%...
versus 94%). The safety profile of the boosted darunavir monotherapy was in line with previous darunavir trials and there was no development of PI resistance and CD4 counts remained stable during the trial.

“The efficacy shown in this systematic review and in the PROTEA study is promising for certain patient populations. Patients with a CD4 nadir of at least 200 cells/µL could potentially benefit from this treatment simplification. A better understanding of the prognostic factors for response needs further investigation,” said Christiane Moecklinghoff, M.D, Ph.D, Medical Director, Virology, Janssen EMEA. “Our goal is to offer new and effective treatment options for people living with HIV by expanding existing treatment options and simplifying regimens. This has the potential to improve patients’ lives by supporting adherence.”

Antiretroviral drugs, such as PIs, help to suppress viral replication at various stages in the viral lifecycle, but do not eliminate HIV. Standard HIV-drug therapy contains three active components: a backbone of two NRTIs, plus either a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), PI or Integrase Inhibitor (INI).

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus. It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.

About PREZISTA® (darunavir)
Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV-1) infection and can be taken with either ritonavir (indicated for use in adults and pediatric patients from the age of 3) or cobicistat (indicated for use in adults only). Darunavir received initial approval in Europe in 2007 for use in HIV-1 infected highly pre-treated patients, with later approvals for treatment-naïve and less experienced adult patients, and then for use in pediatric patients. Darunavir/ritonavir is approved for use in pediatric patients aged 3 (and at least 15 kg body weight) to 17 years.

About Janssen R&D Ireland (Janssen)
At Janssen, we are dedicated to addressing some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen R&D Ireland is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, challenges inherent in new product development, including obtaining regulatory approvals. A further list and description of risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.